[Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003643
German
Original Title:
Dolutegravir/Lamivudin (HIV-Infektion) - 2. Addendum zum Auftrag A19-55
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a19-103.html
Year Published:
2020
URL for published report:
https://www.iqwig.de/download/A19-103_Dolutegravir-Lamivudin_2-Addendum-zum-Auftrag-A19-55_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- HIV
- Anti-HIV Agents
- HIV Infections
- HIV Integrase Inhibitors
- Drug Therapy, Combination
Keywords
- Dolutegravir
- Lamivudine
- HIV Infections
- Benefit Assessment
- NCT02263326
- NCT03446573
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.